Wedbush Downgrades Karuna Therapeutics to Neutral, Announces $330 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico downgraded Karuna Therapeutics (NASDAQ:KRTX) from Outperform to Neutral, while setting a price target of $330.

December 22, 2023 | 4:58 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Karuna Therapeutics was downgraded by Wedbush from Outperform to Neutral, with a new price target of $330.
The downgrade from Outperform to Neutral by a prominent analyst could lead to a neutral short-term impact on KRTX's stock price as it reflects a change in sentiment but is not necessarily negative given the price target suggests potential upside. The importance is high as analyst ratings are closely watched by investors, but not critical as the price target was not reduced. The confidence level is high due to the direct mention and clear action by the analyst.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100